Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase... In the setting of a prospective clinical trial, we determined the predictive value of the methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter for outcome in glioblastoma patients treated with the alkylating agent temozolomide. Expression of this excision repair enzyme has been associated with resistance to alkylating chemotherapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Epidemiology, Biomarkers and Prevention Pubmed

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

Cancer Epidemiology, Biomarkers and Prevention , Volume 10 (6): 416844 – Dec 21, 2004

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.


Abstract

In the setting of a prospective clinical trial, we determined the predictive value of the methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter for outcome in glioblastoma patients treated with the alkylating agent temozolomide. Expression of this excision repair enzyme has been associated with resistance to alkylating chemotherapy.

Loading next page...
 
/lp/pubmed/clinical-trial-substantiates-the-predictive-value-of-o-6-methylguanine-qHsXBblplD

References (17)

ISSN
1078-0432
DOI
10.1158/1078-0432.ccr-03-0384
pmid
15041700

Abstract

In the setting of a prospective clinical trial, we determined the predictive value of the methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter for outcome in glioblastoma patients treated with the alkylating agent temozolomide. Expression of this excision repair enzyme has been associated with resistance to alkylating chemotherapy.

Journal

Cancer Epidemiology, Biomarkers and PreventionPubmed

Published: Dec 21, 2004

There are no references for this article.